Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Liabilities and Shareholders Equity (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 61.28% year-over-year to $5.6 million, compared with a TTM value of $36.8 million through Sep 2025, down 39.98%, and an annual FY2024 reading of $12.3 million, down 2.63% over the prior year.
  • Liabilities and Shareholders Equity was $5.6 million for Q3 2025 at BioRestorative Therapies, down from $8.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $22.5 million in Q4 2021 and bottomed at $2.2 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $12.9 million, with a median of $13.8 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 723.9% in 2022, then tumbled 61.28% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $22.5 million in 2021, then dropped by 26.81% to $16.4 million in 2022, then fell by 23.26% to $12.6 million in 2023, then decreased by 2.63% to $12.3 million in 2024, then crashed by 54.05% to $5.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BRTX at $5.6 million in Q3 2025, $8.5 million in Q2 2025, and $10.3 million in Q1 2025.